Imaging for precision medicine: can V‐P SPECT measure mepolizumab response in asthma?
Respirology Case Reports, 2021 Monoclonal antibody therapies are effective for many but not all people with severe asthma. Precision medicine guides treatment selection using biomarkers to select patients most likely to respond according to their inflammatory endotypes.
Vanessa M. McDonald +5 more
doaj +1 more source
Respiratory Medicine Case Reports, 2022 Severe eosinophilic asthma is associated with a high corticosteroid burden, particularly in patients with comorbid chronic sinusitis/nasal polyps. This case study reports a 33-year-old woman who presented to the severe asthma center with uncontrolled ...
Adel H. Mansur, PhD FRCP
doaj +1 more source
Does asthma impair wealth accumulation or does wealth protect against asthma? [PDF]
, 2016 OBJECTIVE: We investigate the association between adult asthma and wealth, testing whether the disease impairs wealth accumulation (social selection model) or if wealth protects against asthma (social causation model).
Smith, Patricia K., Zagorsky, Jay L.
core +1 more source
Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma : results from two phase 3, randomised, double-blind, placebo-controlled trials [PDF]
, 2020 BACKGROUND: Reslizumab 3 mg/kg administered intravenously is approved for the treatment of severe eosinophilic asthma. We assessed the safety and efficacy of subcutaneous reslizumab 110 mg in two trials in patients with uncontrolled severe asthma and ...
Adir, Yochai +13 more
core +1 more source
Treating severe asthma: Targeting the IL‐5 pathway
Clinical and Experimental Allergy, 2021 Severe asthma is a heterogeneous disease with different phenotypes based on clinical, functional or inflammatory parameters. In particular, the eosinophilic phenotype is associated with type 2 inflammation and increased levels of interleukin (IL)‐4, IL‐5
S. Principe +12 more
semanticscholar +1 more source
Application of an algorithm to analyze patterns of intermittent oral corticosteroid use in asthma
npj Primary Care Respiratory Medicine, 2023 An algorithm to describe patterns of intermittent oral corticosteroid use in the UK (n = 476,167) found that one-third of patients receiving intermittent oral corticosteroids for asthma only had short gaps (
John Haughney +11 more
doaj +1 more source
Obesity, Inflammation, and Severe Asthma: an Update
Current Allergy and Asthma Reports, 2021 Obesity-associated difficult asthma continues to be a substantial problem and, despite a move to address treatable traits affecting asthma morbidity and mortality, it remains poorly understood with limited phenotype-specific treatments.
Varun Sharma, D. Cowan
semanticscholar +1 more source
BMC Pulmonary Medicine, 2021 Background Benralizumab, a monoclonal antibody targeting the human interleukin-5 (IL-5) receptor (IL-5R), was used before marketing authorisation in Spain in a real world setting as part of an early-access programme (EAP) to treat patients with severe ...
Eva Martínez-Moragón +4 more
doaj +1 more source
Depiction of Major Mite Allergens in Severe Allergic Rhinitis with High Mite Perennial Exposure
Turkish Archives of Otorhinolaryngology, 2020 Objective: Airway diseases, including allergic rhinitis, are prompted by specific IgE antibodies against airborne allergens and notably those derived from mites.
Ruperto González-Pérez +3 more
doaj +1 more source
Biologics and global burden of asthma: A worldwide portrait and a call for action
World Allergy Organization Journal, 2021 Biologics for severe asthma can significantly impact on the burden of disease and also have the potential to reduce asthma mortality. By reviewing the literature and contacting the pharmaceutical companies, the present paper aims at providing a worldwide
M. Caminati +6 more
doaj +1 more source